Publications list for Clinical Professor Harry Iland

2014 | 2013 | 2012 | 2009

2014

   
  • Iland, H., Seymour, J., Wei, A. (2014), Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion in Hematology. 21(4), 102-113. [Abstract]

2013

   
  • Firkin, F., Iland, H. (2013), Arsenic: an old enemy now turned friend. Leukemia & Lymphoma. 54(9), 1864-1866. [Abstract]
  • Gibson, J., Iland, H., Larsen, S., Brown, C., Joshua, D. (2013), Leukaemias into the 21st century - part 2: the chronic leukaemias. Internal Medicine Journal. 43(5), 484-494. [Abstract]
  • Iland, H., Seymour, J. (2013), Role of arsenic trioxide in acute promyelocytic leukemia. Current Treatment Options in Oncology. 14(2), 170-184. [Abstract]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P., Iland, H., Fromm, P., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2013), Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal. 3, e148. [Abstract]

2012

   
  • Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012), Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal. 42(11), 1179-1186. [Abstract]
  • Khoo, T., Catalano, A., Supple, S., Chong, L., Yeoh, S., Yeung, S., Iland, H. (2012), Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leukemia & Lymphoma. 54(1), 186-188. [Abstract]
  • Iland, H., Bradstock, K., Supple, S., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., Reynolds, J., Di Iulio, J., Tiley, C., Taylor, K., Filshie, R., Seldon, M., Taper, J., Szer, J., Moore, J., Bashford, J., Seymour, J. (2012), All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 120(8), 1570-1580. [Abstract]
  • Iland, H., Bradstock, K., Seymour, J., Hertzberg, M., Grigg, A., Taylor, K., Catalano, J., Cannell, P., Horvath, N., Deveridge, S., Browett, P., Brighton, T., Chong, L., Springall, F., Ayling, J., Catalano, A., Supple, S., Collins, M., Di Iulio, J., Reynolds, J. (2012), Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 97(2), 227-234. [Abstract]
  • Ling, S., Lau, E., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012), Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 97(1), 64-72. [Abstract]

2009

   
  • de Zwaan, S., Iland, H., Damian, D. (2009), Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. The Australasian Journal of Dermatology. 50(1), 56-59. [Abstract]